Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates
06:56pm, Thursday, 06'th Nov 2025
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $2.7 per share a year ago.
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
04:15pm, Thursday, 06'th Nov 2025
SAN FRANCISCO , Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable se
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
06:00pm, Thursday, 30'th Oct 2025
SAN FRANCISCO , Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Confe
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 30'th Oct 2025
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO , Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-ba
Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High?
10:55am, Tuesday, 28'th Oct 2025
The mean of analysts' price targets for Nektar (NKTR) points to a 50% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
SAN FRANCISCO , Oct. 22, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonis
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
08:37am, Monday, 13'th Oct 2025
Nektar Therapeutics (NKTR -2.34%) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January.
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
08:41am, Sunday, 05'th Oct 2025
Shares of Nektar Therapeutics (NKTR 0.08%), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly enthusias
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
06:43pm, Sunday, 21'st Sep 2025
Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today
05:34pm, Thursday, 18'th Sep 2025
Clinical-stage biotech Nektar Therapeutics (NKTR 15.06%) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances
Why Is Nektar Therapeutics Stock Trading Lower On Thursday?
02:31pm, Thursday, 18'th Sep 2025
Nektar Therapeutics Inc. NKTR on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 202
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
08:45am, Thursday, 18'th Sep 2025
Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis High dose rezpegaldesleukin achieved statistical significance on multiple patient-reporte
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
07:00am, Tuesday, 09'th Sep 2025
SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
12:30pm, Monday, 08'th Sep 2025
Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.
